CL2016000379A1 - Composiciones y métodos terapéuticos para reducción acelerada de plagas - Google Patents

Composiciones y métodos terapéuticos para reducción acelerada de plagas

Info

Publication number
CL2016000379A1
CL2016000379A1 CL2016000379A CL2016000379A CL2016000379A1 CL 2016000379 A1 CL2016000379 A1 CL 2016000379A1 CL 2016000379 A CL2016000379 A CL 2016000379A CL 2016000379 A CL2016000379 A CL 2016000379A CL 2016000379 A1 CL2016000379 A1 CL 2016000379A1
Authority
CL
Chile
Prior art keywords
accelerated
compositions
therapeutic methods
pest reduction
pest
Prior art date
Application number
CL2016000379A
Other languages
English (en)
Inventor
Kenneth Eugene Lebioda
Jan Ove Johansson
F Allan Gordon
Fabrizio Simone Chiacchia
Christopher Ross Armstrong Halliday
Ewelina B Kulikowski
Original Assignee
Resverlogix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resverlogix Corp filed Critical Resverlogix Corp
Publication of CL2016000379A1 publication Critical patent/CL2016000379A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSICION FARMACEUTICA QUE COMPRENDE ROSUVASTATINA Y 2- (- (2-HIDROXIETOXIi) -3,5- DIMETILFENIL) -5, 7-DIMETOXIQUINAZOLIN-4 (3H) -ONA: Y UNMETODO PARA TRATAR O PREVENIR UN TRASTORNO RELACIONADO CON COLESTEROL Y LIPIDOS. (378-13)
CL2016000379A 2013-08-21 2016-02-19 Composiciones y métodos terapéuticos para reducción acelerada de plagas CL2016000379A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361868386P 2013-08-21 2013-08-21

Publications (1)

Publication Number Publication Date
CL2016000379A1 true CL2016000379A1 (es) 2016-08-26

Family

ID=52484226

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000379A CL2016000379A1 (es) 2013-08-21 2016-02-19 Composiciones y métodos terapéuticos para reducción acelerada de plagas

Country Status (14)

Country Link
US (1) US20160206617A1 (es)
EP (1) EP3035934A4 (es)
JP (1) JP2016528275A (es)
KR (1) KR20160043117A (es)
CN (1) CN105473144A (es)
AU (1) AU2014310369A1 (es)
BR (1) BR112016003584A8 (es)
CA (1) CA2921985A1 (es)
CL (1) CL2016000379A1 (es)
EA (1) EA201690284A1 (es)
HK (1) HK1219434A1 (es)
IL (1) IL244166A0 (es)
MX (1) MX2016002302A (es)
WO (1) WO2015025226A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
CA2992231C (en) 2009-03-18 2022-03-29 Resverlogix Corp. Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents
KR20190091564A (ko) 2009-04-22 2019-08-06 리스버로직스 코퍼레이션 신규한 소염제
CN103945848B (zh) 2011-11-01 2016-09-07 雷斯韦洛吉克斯公司 被取代的喹唑啉酮的口服即释制剂
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
JP2016528276A (ja) * 2013-08-21 2016-09-15 レスバーロジックス コーポレイション プラーク退縮を促進するための組成物及び治療法
KR102662814B1 (ko) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법
US20220370452A1 (en) * 2019-11-05 2022-11-24 Resverlogix Corp. Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
US20230241064A1 (en) * 2020-01-08 2023-08-03 Resverlogix Corp. Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556545A (en) * 2002-03-22 2009-03-31 Novartis Ag Combination comprising a beta-hydroxy-beta-methylglutaryl-co-enzyme-A reductase inhibitor and a glucagon-like peptide-1 agonist
US20080085911A1 (en) * 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
DK2118074T3 (en) * 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
WO2012112531A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
AU2014205553A1 (en) * 2013-01-08 2015-07-09 Volant Holdings Gmbh Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
JP2016528276A (ja) * 2013-08-21 2016-09-15 レスバーロジックス コーポレイション プラーク退縮を促進するための組成物及び治療法

Also Published As

Publication number Publication date
AU2014310369A2 (en) 2016-04-21
EP3035934A4 (en) 2017-04-26
EP3035934A2 (en) 2016-06-29
WO2015025226A2 (en) 2015-02-26
BR112016003584A8 (pt) 2018-01-30
AU2014310369A1 (en) 2016-03-10
JP2016528275A (ja) 2016-09-15
MX2016002302A (es) 2016-06-15
EA201690284A1 (ru) 2016-08-31
US20160206617A1 (en) 2016-07-21
CN105473144A (zh) 2016-04-06
KR20160043117A (ko) 2016-04-20
WO2015025226A3 (en) 2015-06-25
WO2015025226A9 (en) 2015-12-03
IL244166A0 (en) 2016-04-21
HK1219434A1 (zh) 2017-04-07
CA2921985A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
CL2016000379A1 (es) Composiciones y métodos terapéuticos para reducción acelerada de plagas
CL2018000429A1 (es) Moduladores de la expresión de kras
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
MX2019001125A (es) Inhibidores de cinasa macrociclica.
PH12016500871A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
TW201613887A (en) Antiproliferative compounds and methods of use thereof
CL2015001990A1 (es) Compuestos de pirrolopirimidina substituidos, composiciones de los mismos, y métodos de tratamiento con los mismos.
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
MX2015010829A (es) Compuestos terapeuticos y sus usos.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112015023074A2 (pt) agentes de ligação-met e uso dos mesmos
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017024163A2 (pt) compostos bicíclicos
MX2016002931A (es) Moduladores del receptor x hepatico (lxr).
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
IN2013MU03118A (es)
GB2543709A (en) Pharmaceutical agent